Virtual Care Revolution: Workit Health's Evidence-Based Approach

Opioid treatment has entered a new phase, one where patients receive FDA-approved medications, therapy, and peer support without ever stepping into a clinic. Workit Health has built a telehealth platform that delivers measurable outcomes backed by peer-reviewed research, proving virtual care can outperform traditional models in retention, adherence, and patient satisfaction.

Their research division, Workit Labs, publishes findings in journals like JAMA Network Open and Telemedicine and e-Health, contributing evidence that shapes how regulators and insurers evaluate virtual addiction treatment. The data shows what happens when barriers disappear, and patients control when, where, and how they access care.

Retention Rates That Rewrite Expectations

Sixty-two percent of rural patients remain enrolled in Workit Health three months after starting treatment, compared to 50% in other telemedicine programs. Six-month retention reaches 52%, while comparable services lose patients to 22%. Each percentage point represents lives saved from a crisis claiming more than 140 Americans daily.

Pregnant patients face particularly steep obstacles in accessing opioid treatment. Fear of judgment, scarcity of willing providers, and concerns about child protective services create deadly delays. Workit Health's March 2024 study in JAMA Network Open tracked outcomes among expectant mothers receiving telemedicine care. Ninety-four percent of those who stayed with the platform continued treatment through six weeks postpartum. Every participant tested positive for buprenorphine after delivery, demonstrating perfect medication adherence.

Workit Labs' February 2025 research in Addiction Science & Clinical Practice found that mailing buprenorphine directly to patients' homes improved retention compared to requiring pharmacy pickups. The study quantified what patients already knew: removing friction between prescription approval and medication receipt keeps people engaged.

Research That Influences Policy and Practice

Workit Labs' August 2025 study found that pharmacy barriers prevent 30% of telemedicine patients from accessing buprenorphine despite physician approval. Published in JAMA Network Open, the research exposed systemic failures that had gone largely unmeasured. Policymakers now cite these findings when advocating for mail delivery programs and pharmacy training initiatives.

July 2025 research in the Journal of Patient Experience examined how virtual backgrounds and clinician attire during video appointments influenced patient trust and satisfaction. The study prompted clinics nationwide to reconsider their telehealth protocols, proving that seemingly minor details affect engagement. March 2025 findings in Telemedicine and e-Health documented patient satisfaction rates across rural and urban populations, with high approval rates in both settings.

Workit Labs' April 2025 research in the Journal of General Internal Medicine explored whether GLP-1 receptor agonists, medications originally developed for diabetes, might reduce alcohol cravings. The results suggested new treatment pathways for alcohol use disorder, prompting additional clinical trials.

Whole-Person Care Delivered Through Screens

Seventy-eight percent of members beginning opioid treatment carry depression diagnoses, while eighty-one percent screen positive for anxiety. Half show moderate to severe depressive symptoms at intake. Workit Health's model addresses these co-occurring conditions through integrated care teams accessible via smartphone.

Patients schedule video appointments with licensed prescribers, message therapists throughout the week, join peer support groups, and track their progress through a mobile application. Evening and weekend availability accommodates work schedules that might otherwise force people to choose between paychecks and appointments. Robin McIntosh and Lisa McLaughlin, the company's founders, built these features after navigating America's fragmented addiction infrastructure themselves.

99% of participants tested positive for buprenorphine at all checkpoints, indicating medication adherence remained strong despite distances from medical offices. Seventy-nine percent tested negative for unexpected substances, though Workit Health's harm-reduction philosophy allows the remaining twenty-one percent to continue care without dismissal. Engagement persists because the model meets patients where they exist geographically, technologically, and emotionally.